LYNAVOY

At a glance

Key dates

1. Approval

   FDA approval date of this drug product.

   Mar 17, 2026

   3 mo ago

2. Today

3. Exclusivity ends · NCE

   New chemical entity exclusivity (5 years)

   Mar 17, 2031

   in 4 yr 10 mo

4. Patent 9040518 expires

   Listed drug substance patent expiration.

   Sep 06, 2031

   in 5 yr 4 mo

5. Exclusivity ends · ODE-517

   Orphan-drug exclusivity (7 years)

   Mar 17, 2033

   in 6 yr 10 mo

Pharmaceutical detail

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (2)

• NCENew chemical entity exclusivity (5 years)

  Mar 17, 2031

  in 4 yr 10 mo

• ODE-517Orphan-drug exclusivity (7 years)

  Mar 17, 2033

  in 6 yr 10 mo

Listed patents (1)